NCT00834665View on ClinicalTrials.gov

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

hTERT vaccine, GM-CSF, PCV, T cell infusion

hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion

BIOLOGICAL

GM-CSF, PCV, T cell infusion

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion

Trial Locations (2)

19104

University of Pennsylvania, Philadelphia

21201

Greenbaum Cancer Center, Baltimore

All Listed Sponsors
collaborator

University of Maryland, College Park

OTHER

lead

University of Pennsylvania

OTHER

NCT00834665 - Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | Biotech Hunter | Biotech Hunter